In this issue of the Archives, Ray et al1 and de Lorgeril et al2 reignite the long-simmering controversy concerning the use of lipid-lowering therapy for the primary prevention of cardiovascular and cerebrovascular events. Each article provides a different and valuable perspective.
Green LA. Cholesterol-Lowering Therapy for Primary Prevention: Still Much We Don't Know. Arch Intern Med. 2010;170(12):1007–1008. doi:10.1001/archinternmed.2010.168
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.